Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice
暂无分享,去创建一个
[1] D. Graham. Therapeutic roles of selective COX-2 inhibitors , 2002 .
[2] J. Vane,et al. Therapeutic Roles Of Selective Cox-2 Inhibitors , 2001 .
[3] Thomas N. Sato,et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. , 2000, The Journal of clinical investigation.
[4] D. Grönemeyer,et al. Usefulness of topography of coronary calcium by electron-beam computed tomography in predicting the natural history of coronary atherosclerosis. , 2000, The American journal of cardiology.
[5] R. Cohen,et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[6] G. FitzGerald,et al. TP or not TP: primary mediators in a close runoff? , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[7] G. FitzGerald,et al. Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo , 2000 .
[8] C Warlow,et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. , 2000, Stroke.
[9] G. FitzGerald,et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. , 2000, The Journal of clinical investigation.
[10] G. Garcı́a-Cardeña,et al. Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesis a , 2000, Annals of the New York Academy of Sciences.
[11] G. FitzGerald,et al. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation , 2000, Nature Medicine.
[12] P. Isakson,et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison , 1999, The Lancet.
[13] D. Graham,et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. , 1999, JAMA.
[14] P. Libby,et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.
[15] M. Condorelli,et al. Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. , 1999, Cardiovascular research.
[16] N. Voelkel,et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.
[17] D. Fitzgerald,et al. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. , 1999, Rheumatology.
[18] G. FitzGerald,et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.
[19] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[21] P. Mannon,et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. , 1998, The Journal of clinical investigation.
[22] D. Fitzgerald,et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. , 1998, The Journal of pharmacology and experimental therapeutics.
[23] D. Rader,et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice , 1998, Nature Medicine.
[24] M. Feldman,et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.
[25] T. Sugimura,et al. Suppression of Intestinal Polyp Development by Nimesulide, a Selective Cyclooxygenase‐2 Inhibitor, in Min Mice , 1997, Japanese journal of cancer research : Gann.
[26] S. Narumiya,et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.
[27] J. Lehmann,et al. Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.
[28] K. Schrör,et al. Thromboxane A2 potentiates thrombin-induced proliferation of coronary artery smooth muscle cells. , 1997, Advances in experimental medicine and biology.
[29] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[30] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[31] T. Ogihara,et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. , 1995, Biochemical and biophysical research communications.
[32] J. Maclouf,et al. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays. , 1995, Biochimica et biophysica acta.
[33] S. Iacobelli,et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.
[34] R. Collins,et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials , 1994, BMJ.
[35] J. Maclouf,et al. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[36] C. Thiemermann,et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[37] J. Maclouf,et al. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. , 1993, The Journal of biological chemistry.
[38] H. Hecker,et al. Dose‐Dependent Effect of Aspirin on Carotid Atherosclerosis , 1993, Circulation.
[39] S. Hart,et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. , 1992, The Journal of biological chemistry.
[40] G. FitzGerald. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. , 1991, The American journal of cardiology.
[41] G. FitzGerald,et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] R. Erikson,et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[43] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[44] Ogletree Ml. Overview of physiological and pathophysiological effects of thromboxane A2. , 1987 .
[45] Davies Mj. Thrombosis in acute myocardial infarction and sudden death. , 1987 .
[46] G. FitzGerald,et al. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.
[47] G. FitzGerald,et al. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. , 1986, Circulation.
[48] G. FitzGerald,et al. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography--negative-ion chemical ionization mass spectrometry. , 1985, Analytical biochemistry.
[49] E. Falk. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.
[50] C. Patrono,et al. Physiologic variables affecting thromboxane B2 production in human whole blood. , 1985, Thrombosis research.
[51] A. K. Pedersen,et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.
[52] V. Tertov,et al. Regression of atherosclerotic manifestations in primary culture of human aortic cells: effects of prostaglandins. , 1984, Biomedica biochimica acta.
[53] D. Cowan. Platelet Adherence to Collagen: Role of Prostaglandin—Thromboxane Synthesis , 1981, British journal of haematology.
[54] J. Oates,et al. Estimated rate of prostacyclin secretion into the circulation of normal man. , 1981, The Journal of clinical investigation.
[55] Tschopp Tb,et al. Platelet adhesion and aggregation in arteries of rats, rabbits and guinea pigs in vivo and in vitro correlate negatively with their prostacyclin (PG I2) production. , 1979 .
[56] F. Fitzpatrick,et al. Platelet rich plasma transforms exogenous prostaglandin endoperoxide H2 into thromboxane A2. , 1977, Prostaglandins.
[57] J. Vane,et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.
[58] M. Hamberg,et al. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides , 1976, Nature.
[59] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .